




## Allison Betof, MD, PhD, FASCO

Associate Professor of Medicine (Oncology)

Medicine - Oncology

 NIH Biosketch available Online

 Curriculum Vitae available Online

### CLINICAL OFFICE (PRIMARY)

- **Stanford Cancer Center**

900 Blake Wilbur Dr

3rd Fl

Stanford, CA 94305

**Tel** (650) 498-6000

**Fax** (650) 724-1445

### Bio

---

#### BIO

Dr. Allison Betof is an Associate Professor of Medicine (Oncology), Director of the Melanoma Program, Director of Solid Tumor Cellular Therapy, and Mark & Mary Stevens Endowed Scholar in Melanoma at Stanford University School of Medicine. Dr. Betof completed her MD and PhD at Duke University, Internal Medicine residency at Massachusetts General Hospital (Harvard University) and Medical Oncology Fellowship at Memorial Sloan Kettering Cancer Center. Dr. Betof's laboratory focuses on understanding resistance to immune checkpoint blockade and cellular therapies for melanoma and other solid tumors. She is the Principal Investigator of clinical trials exploring novel treatments for immunotherapy-refractory melanoma and is internationally recognized for her expertise in brain/CNS metastasis and the use of novel cellular therapies. Dr. Betof has been a pioneer in the use of commercial tumor infiltrating lymphocyte (TIL) therapy for the treatment of melanoma and other solid tumors. She has received funding and awards for her clinical and translational investigative work from multiple high-profile organizations, including the American Society of Clinical Oncology (ASCO), National Institutes of Health (NIH), Melanoma Research Alliance, and Melanoma Research Foundation.

#### CLINICAL FOCUS

- Melanoma
- Cellular Therapy
- Medical Oncology

#### ACADEMIC APPOINTMENTS

- Associate Professor - University Medical Line, Medicine - Oncology
- Member, Stanford Cancer Institute

#### ADMINISTRATIVE APPOINTMENTS

- Mark and Mary Stevens Endowed Faculty Scholar, School of Medicine, (2023- present)
- Medical Director (Cancer Center Program Physician Leader), Melanoma Oncology, School of Medicine, (2023- present)
- Director, Advanced Melanoma Program, School of Medicine, (2023- present)

- Director, Solid Tumor Cell Therapy, School of Medicine, (2023- present)
- Leader, Melanoma & Cutaneous Oncology Clinical Research Group, School of Medicine, (2023- present)
- Co-Director, Pigmented Lesion & Melanoma Clinic, School of Medicine, (2023- present)

## HONORS AND AWARDS

- Innovation of Care Award, Stanford Healthcare (2025)

## PROFESSIONAL EDUCATION

- Board Certification: Medical Oncology, American Board of Internal Medicine (2018)
- Fellowship: Memorial Sloan Kettering Cancer Center (2019) NY
- Board Certification: Internal Medicine, American Board of Internal Medicine (2016)
- Residency: Massachusetts General Hospital Internal Medicine Residency (2016) MA
- Medical Education: Duke University School of Medicine (2013) NC

## Research & Scholarship

---

### CLINICAL TRIALS

- A Randomized, Phase 2/3 Study to Investigate the Efficacy and Safety of RP2 in Combination With Nivolumab in Immune Checkpoint Inhibitor-Naïve Adult Patients With Metastatic Uveal Melanoma, Recruiting
- Expanded Access Program of AMTAGVI That is Out of Specification for Commercial Release, Recruiting
- Expanded Access Protocol (EAP) for Nonconforming (NC) Afami-cel, Recruiting
- Gene Modified Immune Cells (IL13Ralpha2 CAR T Cells) After Conditioning Regimen for the Treatment of Stage IIIC or IV Melanoma or Metastatic Solid Tumors, Recruiting
- Safety and Efficacy of OBX-115 in Advanced Solid Tumors, Recruiting
- SUPRAME-ACEngine® IMA203 vs. Investigator's Choice of Treatment in Previously Treated, Unresectable or Metastatic Cutaneous Melanoma, Recruiting
- VO and Nivolumab vs Physician's Choice in Advanced Melanoma That Progressed on Anti-PD-1 & Anti-CTLA-4 Drugs (IGNYTE-3), Recruiting
- A Study to Investigate LYL845 in Adults With Solid Tumors, Not Recruiting
- IMC-F106C Regimen Versus Nivolumab Regimens in Previously Untreated Advanced Melanoma (PRISM-MEL-301), Not Recruiting
- Phase I, Open-Label, Study of Tumor Infiltrating Lymphocytes Engineered With Membrane Bound IL15 Plus Acetazolamide in Adult Patients With Metastatic Melanoma, Not Recruiting
- Using Nivolumab Alone or With Cabozantinib to Prevent Mucosal Melanoma Return After Surgery, Not Recruiting
- Trial of Relatlimab, Nivolumab, and Ipilimumab in Patients With Asymptomatic and Symptomatic Melanoma Brain Metastases, Not Specified

## Publications

---

### PUBLICATIONS

- **Metastatic Uveal Melanoma Surveillance: A Delphi Panel Consensus.** *Cancers*  
Alban, J., Bowen, R. C., Reichstein, D. A., McKean, M., Lutzky, J., Weis, E., Carvajal, R. D., Dulka, S., Morse, B. G., Butler, M. O., Rapisuwon, S., Kim, K. B., Chandrasekaran, et al  
2025; 18 (1)
- **Association between exercise and clinical outcomes in patients treated with immunotherapy for solid tumors.** *Frontiers in immunology*  
Loo, K., Lavery, J. A., Palmer, J., Guo, W., Underwood, W. P., Moskowitz, C. S., Jones, L. W., Betof, A. S.  
2025; 16: 1694045
- **Consensus-based disease definitions for endocrine immune-related adverse events of immune checkpoint inhibitors.** *Journal for immunotherapy of cancer*

- Zhu, L., Cheung, Y. M., Chiang, C., Gallagher, E. J., Hamnvik, O. R., Mammen, J., Quandt, Z., Jones, R., McDunn, J., Al-Bahadili, H., Angell, T., Bancos, I., Betof Warner, et al  
2025; 13 (10)
- **Proton Craniospinal Irradiation for Patients With Leptomeningeal Metastasis: A Randomized Clinical Trial.** *JAMA oncology*  
Yang, J. T., Yerramilli, D., Pentsova, E., Wolden, S., Young, R. J., Correa, D. D., Imber, B. S., Wijetunga, N. A., Goglia, A. G., Zhang, Z., Zheng, J., Baser, R., Bernstein, et al  
2025
  - **History informing the future of exercise oncology.** *Journal of the National Cancer Institute. Monographs*  
Galvao, D. A., Courneya, K. S., Lucia, A., May, A. M., Mustian, K., Warner, A. B., Joachim, W., Wonders, K., Schmitz, K. H., Newton, R. U.  
2025; 2025 (71): 306-314
  - **The multidisciplinary community of exercise oncology practice: current status and future directions.** *Journal of the National Cancer Institute. Monographs*  
Cao, C., Campbell, K. L., Warner, A. B., Campbell, N., Schwartz, A. L., Cleary, C., Wonders, K., Capozzi, L. C., Ligibel, J. A.  
2025; 2025 (71): 344-350
  - **Long-Term Survival and Biomarker Analysis Evaluating Neoadjuvant Plus Adjuvant Relatlimab (anti-LAG3) and Nivolumab (anti-PD1) in Patients With Resectable Melanoma.** *Journal of clinical oncology : official journal of the American Society of Clinical Oncology*  
Burton, E. M., Milton, D. R., Tetzlaff, M. T., Wani, K., Ross, M. I., Postow, M. A., Lazcano, R., Glitza, I. C., Wong, M. K., Patel, S. P., Diab, A., Gershenwald, J. E., McQuade, et al  
2025: JCO2500494
  - **Programmed death ligand-1 PET imaging in patients with melanoma: a pilot study.** *Melanoma research*  
Pandit-Taskar, N., Mauguen, A., Frosina, D., Jungbluth, A., Busam, K. J., Lyashchenko, S., Schwartz, J., Momtaz, P., Warner, A. B., Smithy, J. W., Shoushtari, A. N., Callahan, M. K., Chapman, et al  
2025
  - **Proceedings of the seventh annual Women in Melanoma Conference.** *Therapeutic advances in medical oncology*  
Najjar, Y. G., Orloff, M., Mitchell, T. C., Bowles, T. L., Betof Warner, A., Bollin, K., Chandra, S., Cohen, J. V., Eroglu, Z., Funchain, P., Gaughan, E., Glitza Oliva, I., Hsu, et al  
2025; 17: 17588359251342039
  - **SUPRAME: A phase 3 trial comparing IMA203, an engineered T-cell receptor expressing T cell therapy (TCR-T) vs investigator's choice in patients with previously treated advanced cutaneous melanoma.**  
Luke, J. J., Warner, A., Chmielowski, B., Diab, A., Gebhardt, C., Hernandez-Aya, L., Hu-Lieskovan, S., Karapetyan, L., Lawrence, D. P., Mckean, M., Mitchell, T. C., Moschos, S. J., Moser, et al  
LIPPINCOTT WILLIAMS & WILKINS.2025: TPS2673
  - **OBX-115 engineered tumor-infiltrating lymphocyte (TIL) cell therapy with regulatable membrane-bound IL15 (mBL15) in patients (pts) with immune checkpoint inhibitor (ICI)-resistant advanced melanoma: Phase 1 results of the Agni-01 multicenter study**  
Chesney, J., In, G., Shoushtari, A., Moyers, J., Samhoury, Y., Johnson, T. T., Amaria, R., Ramsingh, G., Renard, C., Duan, R., McLaughlin, L., Betof Warner, A.  
LIPPINCOTT WILLIAMS & WILKINS.2025
  - **A randomized, phase 2/3 clinical trial investigating RP2 plus nivolumab vs ipilimumab plus nivolumab in immune checkpoint inhibitor-naïve patients with metastatic uveal melanoma.**  
Sacco, J. J., Moser, J. C., Betof Warner, A., Sullivan, R. J., Davar, D., Shoushtari, A., Carvajal, R. D., Patel, S., Joshua, A. M., Hassel, J., Navarro, M., Marpadga, R., Gullo, et al  
LIPPINCOTT WILLIAMS & WILKINS.2025: TPS9597
  - **Role of high-dose interleukin-2 for melanoma in the age of cellular therapy.** *Journal for immunotherapy of cancer*  
Buchbinder, E., Lotze, M. T., Margolin, K. A., Amaria, R., Sarnaik, A., Seery, V., Eroglu, Z., Khaddour, K., Betof Warner, A., Kluger, H. M., Sznol, M., Atkins, M. B., McDermott, et al  
2025; 13 (5)
  - **The Clinical TIL Experience in Melanoma: Past, Present, Future.** *Transplantation and cellular therapy*  
Smithy, J. W., Schoenfeld, A. J., Betof Warner, A.  
2025; 31 (3S): S626-S634
  - **Infections in Patients with Solid Tumors Undergoing Adoptive Cellular Therapy.** *Transplantation and cellular therapy*

- Avutu, V., Algazaq, J. N., Seier, K., Desir-Camille, R., Qin, L. X., Babatunde, O., Adusumilli, P. S., Klebanoff, C. A., Kotecha, R. R., Shoushtari, A. N., Slovin, S., Warner, A. B., Park, et al  
2025
- **Advances in the understanding and therapeutic manipulation of cancer immune responsiveness: a Society for Immunotherapy of Cancer (SITC) review.** *Journal for immunotherapy of cancer*  
Cesano, A., Augustin, R., Barrea, L., Bedognetti, D., Bruno, T. C., Carturan, A., Hammer, C., Ho, W. S., Kather, J. N., Kirchhoff, T., Lu, R. O., McQuade, J., Najjar, et al  
2025; 13 (1)
  - **Proceedings of the seventh annual Women in Melanoma Conference** *THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY*  
Najjar, Y. G., Orloff, M., Mitchell, T. C., Bowles, T. L., Betof Warner, A., Bollin, K., Chandra, S., Cohen, J. V., Eroglu, Z., Funchain, P., Gaughan, E., Glitza Oliva, I., Hsu, et al  
2025; 17
  - **Racial Disparities in Cancer Stage at Diagnosis and Survival for Adolescents and Young Adults.** *JAMA network open*  
Taparra, K., Kekumano, K., Benavente, R., Roberto, L., Gimmen, M., Shontell, R., Cakobau, H., Deo, N., Kinslow, C. J., Betof Warner, A., Deville, C., Shing, J. Z., Vo, et al  
2024; 7 (8): e2430975
  - **Durable complete response in a patient with leptomeningeal melanoma after treatment with dabrafenib, trametinib, and nivolumab.** *Pigment cell & melanoma research*  
Lochrin, S. E., Buonocore, D. J., Young, R. J., Kaley, T. J., Postow, M. A., Wolchok, J. D., Shoushtari, A. N., Momtaz, P., Betof Warner, A. S., Callahan, M. K.  
2024
  - **Adoptive Cell Therapy for Solid Tumors: Current Status in Melanoma and Next-Generation Therapies.** *American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting*  
Haanen, J., Los, C., Phan, G. Q., Betof Warner, A.  
2024; 44 (3): e431608
  - **A phase 1/2 study to investigate the safety and efficacy of OBX-115 engineered tumor-infiltrating lymphocyte (TIL) cell therapy in patients (pts) with advanced solid tumors**  
Schoenfeld, A., Warner, A., Chesney, J., Thomas, S., Hamid, O., In, G., Shoushtari, A., Samhouri, Y., Hari, P. N., Ramsingh, G., Renard, C., Prabhakar, P., Mclaughlin, et al  
LIPPINCOTT WILLIAMS & WILKINS.2024
  - **Contemporary management of patients with advanced melanoma: Utility of an online interactive decision support tool to assess concordance of healthcare professional treatment patterns with expert recommendations**  
Becker, M. N., Rosenthal, K. M., Warner, A., Daud, A., Lipson, E. J., Tarhini, A. A., Tawbi, H. A.  
LIPPINCOTT WILLIAMS & WILKINS.2024
  - **A pilot trial of autologous tumor infiltrating lymphocytes (lifileucel, LN-144) for patients with asymptomatic melanoma brain metastases**  
Warner, A., Smithy, J., Postow, M. A., Panageas, K., Schoenfeld, A., Wolchok, J. D., Shoushtari, A.  
LIPPINCOTT WILLIAMS & WILKINS.2024
  - **Early on-treatment assessment of T-cells, cytokines and tumor DNA with adaptively-dosed nivolumab + ipilimumab: final results from the phase 2 ADAPT-IT study.** *Clinical cancer research : an official journal of the American Association for Cancer Research*  
Smithy, J. W., Kalvin, H. L., Ehrich, F. D., Shah, R., Adamow, M., Raber, V., Maher, C. A., Kleman, J., McIntyre, D. A., Shoushtari, A. N., Betof Warner, A., Callahan, M. K., Momtaz, et al  
2024
  - **Trial in Progress: A Phase 1/2 Study to Investigate the Safety and Efficacy of OBX-115 Engineered Tumor-Infiltrating Lymphocyte (TIL) Cell Therapy in Patients (Pts) with Advanced Solid Tumors**  
Schoenfeld, A. J., Warner, A., Thomas, S. S., Hamid, O., In, G. K., Shoushtari, A. N., Samhouri, Y., Hari, P., Ramsingh, G., Prabhakar, P., Mclaughlin, L., Chesney, J. A.  
CELL PRESS.2024: 881
  - **Defining D-irAEs: consensus-based disease definitions for the diagnosis of dermatologic adverse events from immune checkpoint inhibitor therapy.** *Journal for immunotherapy of cancer*  
Chen, S. T., Semenov, Y. R., Alloo, A., Bach, D. Q., Betof Warner, A., Bougrine, A., Burton, L., Cappelli, L. C., Castells, M., Cohen, J., Dewan, A. K., Fadden, R., Guggina, et al

2024; 12 (4)

- **Expert consensus guidelines on management and best practices for tumor-infiltrating lymphocyte cell therapy.** *Journal for immunotherapy of cancer*  
Betof Warner, A., Hamid, O., Komanduri, K., Amaria, R., Butler, M. O., Haanen, J., Nikiforow, S., Puzanov, I., Sarnaik, A., Bishop, M. R., Schoenfeld, A. J.  
2024; 12 (2)
- **Leptomeningeal Carcinomatosis from Solid Tumor Malignancies: Treatment Strategies and Biomarkers.** *Seminars in neurology*  
Malani, R., Bhatia, A., Warner, A. B., Yang, J. T.  
2023
- **The features and management of acquired resistance to PD1-based therapy in metastatic melanoma.** *European journal of cancer (Oxford, England : 1990)*  
Hepner, A., Versluis, J. M., Wallace, R., Allayous, C., Brown, L. J., Trojaniello, C., Gerard, C. L., Jansen, Y. J., Bhave, P., Neyns, B., Haydon, A., Michielin, O., Mangana, et al  
2023; 196: 113441
- **Exercise as an Immune Boost: Mechanism-Driven Support for Lifestyle Interventions.** *Cancer immunology research*  
Betof Warner, A.  
2023: OF1
- **CD4+ TIL to the rescue of anti-PD-1 failure by targeting MHC-II.** *Clinical cancer research : an official journal of the American Association for Cancer Research*  
Betof Warner, A., Luke, J. J.  
2023
- **Perspectives in Melanoma: meeting report from the Melanoma Bridge (December 1st-3rd, 2022-Naples, Italy).** *Journal of translational medicine*  
Ascierto, P. A., Agarwala, S. S., Warner, A. B., Ernstoff, M. S., Fox, B. A., Gajewski, T. F., Galon, J., Garbe, C., Gastman, B. R., Gershenwald, J. E., Kalinski, P., Krogsgaard, M., Leidner, et al  
2023; 21 (1): 508
- **A pilot trial of autologous tumor infiltrating lymphocytes (lifeluceel, LN-144) for patients with asymptomatic melanoma brain metastases**  
Warner, A., Postow, M. A., Panageas, K., Smithy, J., Schoenfeld, A., Wolchok, J. D., Shoushtari, A.  
LIPPINCOTT WILLIAMS & WILKINS.2023
- **Real-world treatment patterns and outcomes for patients with advanced melanoma treated with immunotherapy or targeted therapy.** *Pharmacoeconomics and drug safety*  
Lee, S., Bennett, A. V., Zhou, X., Betof Warner, A., Trogdon, J. G., Kent, E. E., Lund, J. L.  
2023
- **Diversity, equity, and inclusion in the melanoma research community.** *Pigment cell & melanoma research*  
Portuallo, M. E., Lu, D. Y., Alicea, G. M., Bolling, J., Lee, R., McQuade, J., Warner, A. B., Davies, M., Weeraratna, A., Villanueva, J., Rebecca, V. W.  
2023
- **Beyond the 5-year milestone: Long-term survivorship of melanoma patients treated off-trial with anti-PD-1.** *Pigment cell & melanoma research*  
Loo, K., Kalvin, H. L., Panageas, K. S., Callahan, M. K., Chapman, P. B., Momtaz, P., Shoushtari, A. N., Wolchok, J. D., Postow, M. A., Warner, A. B.  
2023
- **T cell immunotherapies engage neutrophils to eliminate tumor antigen escape variants.** *Cell*  
Hirschhorn, D., Budhu, S., Kraehenbuehl, L., Gigoux, M., Schröder, D., Chow, A., Ricca, J. M., Gasmi, B., De Henau, O., Mangarin, L. M., Li, Y., Hamadene, L., Flamar, et al  
2023; 186 (7): 1432-1447.e17
- **Neoadjuvant relatlimab and nivolumab in resectable melanoma (vol 611, pg 155, 2022) NATURE**  
Amaria, R. N., Postow, M., Burton, E. M., Tetzlaff, M. T., Ross, M. I., Torres-Cabala, C., Glitza, I. C., Duan, F., Milton, D. R., Busam, K., Simpson, L., McQuade, J. L., Wong, et al  
2023: E23

- **Efficacy of immunotherapy for melanoma brain metastases in patients with concurrent corticosteroid exposure.** *CNS oncology*  
Tringale, K. R., Reiner, A. S., Sehgal, R. R., Panageas, K., Betof Warner, A. S., Postow, M. A., Moss, N. S.  
2023; 12 (1): CNS93
- **Decision-Making and Health-Related Quality of Life in Patients with Melanoma Considering Adjuvant Immunotherapy** *ONCOLOGIST*  
Atkinson, T. M., Hay, J. L., Young Kim, S., Schofield, E., Postow, M. A., Momtaz, P., Warner, A., Shoushtari, A. N., Callahan, M. K., Wolchok, J. D., Li, Y., Chapman, P. B.  
2023
- **Real-world outcomes of different lines and sequences of treatment in BRAF-positive advanced melanoma patients.** *Melanoma research*  
Betof Warner, A., Tarhini, A., Kang, B., Nakasato, A., Ling, Y. L., Shah, R., Tang, J., Patel, J.  
2023; 33 (1): 38-49
- **Metformin is associated with improved clinical outcomes in patients with melanoma: a retrospective, multi-institutional study.** *Frontiers in oncology*  
Augustin, R. C., Huang, Z., Ding, F., Zhai, S., McArdle, J., Santisi, A., Davis, M., Sander, C., Davar, D., Kirkwood, J. M., Delgoffe, G. M., Warner, A. B., Najjar, et al  
2023; 13: 1075823
- **Tumor-Infiltrating Lymphocyte Therapy in Melanoma: Facts to the Future.** *Clinical cancer research : an official journal of the American Association for Cancer Research*  
Betof Warner, A., Corrie, P. G., Hamid, O.  
2022
- **Case report: Later onset of NRAS-mutant metastatic melanoma in a patient with a partially-excised giant congenital melanocytic nevus.** *Frontiers in medicine*  
Costa, B. A., Zibara, V., Singh, V., Hamid, O., Gandhi, S., Moy, A. P., Betof Warner, A. S.  
2022; 9: 1086473
- **Randomized Phase II Trial of Proton Craniospinal Irradiation Versus Photon Involved-Field Radiotherapy for Patients With Solid Tumor Leptomeningeal Metastasis.** *Journal of clinical oncology : official journal of the American Society of Clinical Oncology*  
Yang, J. T., Wijetunga, N. A., Pentsova, E., Wolden, S., Young, R. J., Correa, D., Zhang, Z., Zheng, J., Steckler, A., Bucwinska, W., Bernstein, A., Betof Warner, A., Yu, et al  
2022; 40 (33): 3858-3867
- **Neoadjuvant relatlimab and nivolumab in resectable melanoma.** *Nature*  
Amaria, R. N., Postow, M., Burton, E. M., Tetzlaff, M. T., Ross, M. I., Torres-Cabala, C., Glitza, I. C., Duan, F., Milton, D. R., Busam, K., Simpson, L., McQuade, J. L., Wong, et al  
2022; 611 (7934): 155-160
- **Inflammatory vulvar dermatoses following immune checkpoint inhibitor therapy.** *American journal of obstetrics and gynecology*  
Sia, T. Y., Warner, A. B., Noor, S. J., Aviki, E. M., Long Roche, K.  
2022
- **Benefit and toxicity of programmed death-1 blockade vary by ethnicity in patients with advanced melanoma: an international multicentre observational study.** *The British journal of dermatology*  
Bai, X., Shoushtari, A. N., Betof Warner, A., Si, L., Tang, B., Cui, C., Yang, X., Wei, X., Quach, H. T., Cann, C. G., Zhang, M. Z., Pallan, L., Harvey, et al  
2022; 187 (3): 401-410
- **The "Great Debate" at Melanoma Bridge 2021, December 2nd-4th, 2021.** *Journal of translational medicine*  
Ascierto, P. A., Warner, A. B., Blank, C., Caracò, C., Demaria, S., Gershenwald, J. E., Khushalani, N. I., Long, G. V., Luke, J. J., Mehnert, J. M., Robert, C., Rutkowski, P., Tawbi, et al  
2022; 20 (1): 200
- **Adaptive Dosing of Nivolumab + Ipilimumab Immunotherapy Based Upon Early, Interim Radiographic Assessment in Advanced Melanoma (The ADAPT-IT Study).** *Journal of clinical oncology : official journal of the American Society of Clinical Oncology*  
Postow, M. A., Goldman, D. A., Shoushtari, A. N., Betof Warner, A., Callahan, M. K., Momtaz, P., Smithy, J. W., Naito, E., Cugliari, M. K., Raber, V., Eton, O., Nair, S. G., Panageas, et al  
2022; 40 (10): 1059-1067

- **Adoptive Cell Transfer and Vaccines in Melanoma: The Horizon Comes Into View.** *American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting*  
Betof-Warner, A., Sullivan, R. J., Sarnaik, A.  
2022; 42: 1-8
- **Quantitative cerebrospinal fluid circulating tumor cells are a potential biomarker of response for proton craniospinal irradiation for leptomeningeal metastasis.** *Neuro-oncology advances*  
Wijetunga, N. A., Boire, A., Young, R. J., Yamada, Y., Wolden, S., Yu, H., Kris, M., Seidman, A., Betof-Warner, A., Diaz, M., Reiner, A., Malani, R., Pentsova, et al  
2021; 3 (1): vdab181
- **Dermatologic infections in cancer patients treated with checkpoint inhibitors.** *Journal of the American Academy of Dermatology*  
Do, M. H., Barrios, D. M., Phillips, G. S., Postow, M. A., Warner, A. B., Rosenberg, J. E., Noor, S. J., Markova, A., Lacouture, M. E.  
2021; 85 (6): 1528-1536
- **Early Use of High-Dose Glucocorticoid for the Management of irAE Is Associated with Poorer Survival in Patients with Advanced Melanoma Treated with Anti-PD-1 Monotherapy.** *Clinical cancer research : an official journal of the American Association for Cancer Research*  
Bai, X., Hu, J., Betof Warner, A., Quach, H. T., Cann, C. G., Zhang, M. Z., Si, L., Tang, B., Cui, C., Yang, X., Wei, X., Pallan, L., Harvey, et al  
2021; 27 (21): 5993-6000
- **Cyclophosphamide enhances the antitumor potency of GITR engagement by increasing oligoclonal cytotoxic T cell fitness.** *JCI insight*  
Hirschhorn, D., Betof Warner, A., Maniyar, R., Chow, A., Mangarin, L. M., Cohen, A. D., Hamadene, L., Rizzuto, G. A., Budhu, S., Suek, N., Liu, C., Houghton, A. N., Merghoub, et al  
2021; 6 (20)
- **Risks and benefits of reinduction ipilimumab/nivolumab in melanoma patients previously treated with ipilimumab/nivolumab.** *Journal for immunotherapy of cancer*  
Chapman, P. B., Jayaprakasam, V. S., Panageas, K. S., Callahan, M., Postow, M. A., Shoushtari, A. N., Wolchok, J. D., Betof Warner, A.  
2021; 9 (10)
- **Immune checkpoint inhibitors in patients with pre-existing psoriasis: safety and efficacy.** *Journal for immunotherapy of cancer*  
Halle, B. R., Betof Warner, A., Zaman, F. Y., Haydon, A., Bhave, P., Dewan, A. K., Ye, F., Irimeier, R., Mehta, P., Kurtansky, N. R., Lacouture, M. E., Hassel, J. C., Choi, et al  
2021; 9 (10)
- **LAG-3 expression on peripheral blood cells identifies patients with poorer outcomes after immune checkpoint blockade.** *Science translational medicine*  
Shen, R., Postow, M. A., Adamow, M., Arora, A., Hannum, M., Maher, C., Wong, P., Curran, M. A., Hollmann, T. J., Jia, L., Al-Ahmadie, H., Keegan, N., Funt, et al  
2021; 13 (608)
- **Ipilimumab versus ipilimumab plus anti-PD-1 for metastatic melanoma reply** *LANCET ONCOLOGY*  
da Silva, I., Ahmed, T., Reijers, I. L. M., Warner, A., Patrinely, J., Serra-Bellver, P., Allayous, C., Mangana, J., Zimmer, L., Trojaniello, C., Klein, O., Gerard, C. L., Michielin, et al  
2021; 22 (8): E343-E344
- **Consensus disease definitions for neurologic immune-related adverse events of immune checkpoint inhibitors.** *Journal for immunotherapy of cancer*  
Guidon, A. C., Burton, L. B., Chwalisz, B. K., Hillis, J., Schaller, T. H., Amato, A. A., Betof Warner, A., Brastianos, P. K., Cho, T. A., Clardy, S. L., Cohen, J. V., Dietrich, J., Dougan, et al  
2021; 9 (7)
- **Ipilimumab alone or ipilimumab plus anti-PD-1 therapy in patients with metastatic melanoma resistant to anti-PD-(L)1 monotherapy: a multicentre, retrospective, cohort study.** *The Lancet. Oncology*  
Pires da Silva, I., Ahmed, T., Reijers, I. L., Weppler, A. M., Betof Warner, A., Patrinely, J. R., Serra-Bellver, P., Allayous, C., Mangana, J., Nguyen, K., Zimmer, L., Trojaniello, C., Stout, et al  
2021; 22 (6): 836-847
- **Therapeutic Implications of Detecting MAPK-Activating Alterations in Cutaneous and Unknown Primary Melanomas.** *Clinical cancer research : an official journal of the American Association for Cancer Research*  
Shoushtari, A. N., Chatila, W. K., Arora, A., Sanchez-Vega, F., Kantheti, H. S., Rojas Zamalloa, J. A., Krieger, P., Callahan, M. K., Betof Warner, A., Postow, M. A., Momtaz, P., Nair, S., Ariyan, et al

2021; 27 (8): 2226-2235

- **Success and failure of additional immune modulators in steroid-refractory/resistant pneumonitis related to immune checkpoint blockade.** *Journal for immunotherapy of cancer*  
Beattie, J., Rizvi, H., Fuentes, P., Luo, J., Schoenfeld, A., Lin, I. H., Postow, M., Callahan, M., Voss, M. H., Shah, N. J., Betof Warner, A., Chawla, M., Hellmann, et al  
2021; 9 (2)
- **Factors Determining Long-Term Antitumor Responses to Immune Checkpoint Blockade Therapy in Melanoma.** *Frontiers in immunology*  
Loo, K., Smithy, J. W., Postow, M. A., Betof Warner, A.  
2021; 12: 810388
- **The future of cancer immunotherapy: microenvironment-targeting combinations.** *Cell research*  
Murciano-Goroff, Y. R., Warner, A. B., Wolchok, J. D.  
2020; 30 (6): 507-519
- **Long-Term Outcomes and Responses to Retreatment in Patients With Melanoma Treated With PD-1 Blockade.** *Journal of clinical oncology : official journal of the American Society of Clinical Oncology*  
Betof Warner, A., Palmer, J. S., Shoushtari, A. N., Goldman, D. A., Panageas, K. S., Hayes, S. A., Bajwa, R., Momtaz, P., Callahan, M. K., Wolchok, J. D., Postow, M. A., Chapman, P. B.  
2020; 38 (15): 1655-1663
- **Ipilimumab (IPI) alone or in combination with anti-PD-1 (IPI+PD1) in patients (pts) with metastatic melanoma (MM) resistant to PD1 monotherapy.**  
Da Silva, I., Ahmed, T., Lo, S., Reijers, I. L. M., Wepler, A., Warner, A., Patrinely, J., Serra-Bellver, P., Lebbe, C., Mangana, J., Nguyen, K., Zimmer, L., Ascierto, et al  
LIPPINCOTT WILLIAMS & WILKINS.2020
- **Another Victory for Immune Checkpoint Blockade in Melanoma: Adjuvant Ipilimumab Over Interferon** *JOURNAL OF CLINICAL ONCOLOGY*  
Betof Warner, A., Postow, M. A.  
2020; 38 (6): 529+
- **Selective inhibition of low-affinity memory CD8+ T cells by corticosteroids.** *The Journal of experimental medicine*  
Tokunaga, A., Sugiyama, D., Maeda, Y., Warner, A. B., Panageas, K. S., Ito, S., Togashi, Y., Sakai, C., Wolchok, J. D., Nishikawa, H.  
2019; 216 (12): 2701-2713
- **Modifiable Host Factors in Melanoma: Emerging Evidence for Obesity, Diet, Exercise, and the Microbiome.** *Current oncology reports*  
Warner, A. B., McQuade, J. L.  
2019; 21 (8): 72
- **Can Exercise-Induced Modulation of the Tumor Physiologic Microenvironment Improve Antitumor Immunity?** *Cancer research*  
Zhang, X., Ashcraft, K. A., Betof Warner, A., Nair, S. K., Dewhirst, M. W.  
2019; 79 (10): 2447-2456
- **Exercise as Adjunct Therapy in Cancer** *SEMINARS IN RADIATION ONCOLOGY*  
Ashcraft, K. A., Warner, A., Jones, L. W., Dewhirst, M. W.  
2019; 29 (1): 16-24
- **Bigger Is Not Always Better: Tumor Size and Prognosis in Advanced Melanoma** *CLINICAL CANCER RESEARCH*  
Warner, A., Postow, M. A.  
2018; 24 (20): 4915-4917
- **Combination Controversies: Checkpoint Inhibition Alone or in Combination for the Treatment of Melanoma?** *Oncology (Williston Park, N.Y.)*  
Warner, A. B., Postow, M. A.  
2018; 32 (5): 228-34
- **Combination Controversies: Checkpoint Inhibition Alone or in Combination for the Treatment of Melanoma?** *ONCOLOGY-NEW YORK*  
Warner, A., Postow, M. A.  
2018; 32 (5): 228-234
- **The brim of uncertainty in adjuvant treatment of melanoma** *LANCET ONCOLOGY*

- Warner, A., Postow, M. A.  
2018; 19 (4): 436-437
- **Peripheral blood clinical laboratory variables associated with outcomes following combination nivolumab and ipilimumab immunotherapy in melanoma.** *Cancer medicine*  
Rosner, S., Kwong, E., Shoushtari, A. N., Friedman, C. F., Betof, A. S., Brady, M. S., Coit, D. G., Callahan, M. K., Wolchok, J. D., Chapman, P. B., Panageas, K. S., Postow, M. A.  
2018; 7 (3): 690-697
  - **Safety of resuming anti-PD-1 in patients with immune-related adverse events (irAEs) during combined anti-CTLA-4 and anti-PD1 in metastatic melanoma.** *Annals of oncology : official journal of the European Society for Medical Oncology*  
Pollack, M. H., Betof, A., Dearden, H., Rapazzo, K., Valentine, I., Brohl, A. S., Ancell, K. K., Long, G. V., Menzies, A. M., Eroglu, Z., Johnson, D. B., Shoushtari, A. N.  
2018; 29 (1): 250-255
  - **End-of-Life Care for Patients with Potentially Resectable Pancreatic Cancer Who Received Radiation Therapy**  
Yerramilli, D., Betof, A., Drapek, L. C., Wo, J. Y., Hong, T. S., Nipp, R.  
ELSEVIER SCIENCE INC.2017: E529-E530
  - **Impact of Age on Outcomes with Immunotherapy for Patients with Melanoma.** *The oncologist*  
Betof, A. S., Nipp, R. D., Giobbie-Hurder, A., Johnpulle, R. A., Rubin, K., Rubinstein, S. M., Flaherty, K. T., Lawrence, D. P., Johnson, D. B., Sullivan, R. J.  
2017; 22 (8): 963-971
  - **Efficacy and Mechanisms of Aerobic Exercise on Cancer Initiation, Progression, and Metastasis: A Critical Systematic Review of In Vivo Preclinical Data** *CANCER RESEARCH*  
Ashcraft, K. A., Peace, R. M., Betof, A. S., Dewhirst, M. W., Jones, L. W.  
2016; 76 (14): 4032-4050
  - **Modulation of murine breast tumor vascularity, hypoxia and chemotherapeutic response by exercise.** *Journal of the National Cancer Institute*  
Betof, A. S., Lascola, C. D., Weitzel, D., Landon, C., Scarbrough, P. M., Devi, G. R., Palmer, G., Jones, L. W., Dewhirst, M. W.  
2015; 107 (5)
  - **Effects and potential mechanisms of exercise training on cancer progression: A translational perspective** *BRAIN BEHAVIOR AND IMMUNITY*  
Betof, A. S., Dewhirst, M. W., Jones, L. W.  
2013; 30: S75-S87
  - **Exercise modulation of the host-tumor interaction in an orthotopic model of murine prostate cancer.** *Journal of applied physiology (Bethesda, Md. : 1985)*  
Jones, L. W., Antonelli, J., Masko, E. M., Broadwater, G., Lascola, C. D., Fels, D., Dewhirst, M. W., Dyck, J. R., Nagendran, J., Flores, C. T., Betof, A. S., Nelson, E. R., Pollak, et al  
2012; 113 (2): 263-72
  - **Carbonic anhydrase IX is a predictive marker of doxorubicin resistance in early-stage breast cancer independent of HER2 and TOP2A amplification.** *British journal of cancer*  
Betof, A. S., Rabbani, Z. N., Hardee, M. E., Kim, S. J., Broadwater, G., Bentley, R. C., Snyder, S. A., Vujaskovic, Z., Oosterwijk, E., Harris, L. N., Horton, J. K., Dewhirst, M. W., Blackwell, et al  
2012; 106 (5): 916-22
  - **Sleeve gastrectomy strictures: technique for robotic-assisted strictureplasty** *SURGERY FOR OBESITY AND RELATED DISEASES*  
Sudan, R., Kasotakis, G., Betof, A., Wright, A.  
2010; 6 (4): 434-436
  - **Effect of pazopanib on tumor microenvironment and liposome delivery.** *Molecular cancer therapeutics*  
Tailor, T. D., Hanna, G., Yarmolenko, P. S., Dreher, M. R., Betof, A. S., Nixon, A. B., Spasojevic, I., Dewhirst, M. W.  
2010; 9 (6): 1798-808
  - **A phase I/II study of neoadjuvant liposomal doxorubicin, paclitaxel, and hyperthermia in locally advanced breast cancer.** *International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group*  
Vujaskovic, Z., Kim, D. W., Jones, E., Lan, L., McCall, L., Dewhirst, M. W., Craciunescu, O., Stauffer, P., Liotcheva, V., Betof, A., Blackwell, K.

